Drug Trial Radar · NCT06513806
Granisetron Versus Pethidine in Treatment of Post Spinal Shivering in Cesarean Sections
Last checked: Nov 20, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
330
Actual
Start
Aug 1, 2024
Primary completion
Sep 25, 2024
Study completion Sep 28, 2024
Sponsor
- Lead sponsor
- Ain Shams UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Granisetron Versus Pethidine in Treatment of Post Spinal Shivering in Cesarean Sections
Conditions
- Anesthesia; Adverse Effect, Spinal and Epidural
Interventions
Granisetron 1 Mg/mL Intravenous SolutionDrug
will receive granisetron 3 mg iv bolus
PethidinDrug
will receive pethidine 25 mg iv bolus
Primary outcomes
What the sponsor says the trial is designed to measure.
- treating post spinal shiveringTime frame: perioperatively/periprocedurally
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ain Shams University
Cairo, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.